Company CVAbout Sanofi India Ltd 
Sanofi India Ltd
Small Cap
Pharmaceuticals & Biotechnology
Sanofi India Limited, (Previously known as Aventis Pharma Limited) was incorporated in May, 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012. The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market. The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals. It has its own manufacturing facility at Goa.
Company Coordinates
Company Details
Sanofi Hse 117-B Saki Vihar Rd, L&T Business Park Powai Mumbai Maharashtra : 400072
Registrar Details
Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai
Capital StructureCapital Structure
Present Equity Capital
INR None Cr
Number of Shares
None Cr
Face Value
INR None
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
No Details Available.
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 16 Schemes (10.42%)
FIIs
Held by 135 FIIs (5.57%)
Promoter with highest holding
Hoechst Gmbh (60.37%)
Highest Public shareholder
Life Insurance Corporation Of India - P & Gs Fund (5.95%)
Individual Investors Holdings
9.08%
Board of Directors
Management
Designation
Remuneration
Aditya Narayan
Chairman & Independent Directo
32.9 lacs
Usha Thorat
Independent Director
30.1 lacs
Vaibhav KARANDIKAR
Whole Time Director & CFO
2.0 cr
Rahul Bhatnagar
Independent Director
32.5 lacs
Marc-Antoine Lucchini
Director
0
Annapurna Das
Director
0
Rodolfo Hrosz
Managing Director
0
Radhika Shah
Company Secretary
0
Renee Amonkar
WTD & Additional Director
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Pharmaceuticals
2,594.00
93.62%
Business Auxiliary Services
145.70
5.26%
Export Incentives
26.60
0.96%
Pharmaceuticals
Pharmaceuticals
Business Auxiliary Services
Business Auxiliary Services
Export Incentives
Export Incentives
Stock DNARevenue and Profits:
Net Sales:
475 Cr
(Quarterly Results - Sep 2025)
Net Profit:
76 Cr
Pharmaceuticals & Biotechnology
INR 9,933 Cr (Small Cap)
27.00
34
4.38%
-0.37
47.39%
12.90
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
